JP2014507422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507422A5 JP2014507422A5 JP2013551360A JP2013551360A JP2014507422A5 JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5 JP 2013551360 A JP2013551360 A JP 2013551360A JP 2013551360 A JP2013551360 A JP 2013551360A JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- formula
- substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- -1 —COOR 2 Chemical group 0.000 claims 1
- 0 CC(C)(C1CC2)C(**)=CC[C@]1(C)C(CC1)[C@]2(C)[C@@]2(C)[C@]1C(CCC1)[C@@]1(C*)CC2 Chemical compound CC(C)(C1CC2)C(**)=CC[C@]1(C)C(CC1)[C@]2(C)[C@@]2(C)[C@]1C(CCC1)[C@@]1(C*)CC2 0.000 description 1
- NUMIDZGOCYWZCT-UHFFFAOYSA-N CCCC(N(CC1)CCS1(=O)=O)=O Chemical compound CCCC(N(CC1)CCS1(=O)=O)=O NUMIDZGOCYWZCT-UHFFFAOYSA-N 0.000 description 1
- IWNOLSWCBOWZCW-UHFFFAOYSA-N CCCC(NC(CC)=O)=O Chemical compound CCCC(NC(CC)=O)=O IWNOLSWCBOWZCW-UHFFFAOYSA-N 0.000 description 1
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 1
- VWIIJDNADIEEDB-UHFFFAOYSA-N CN(CCO1)C1=O Chemical compound CN(CCO1)C1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437870P | 2011-01-31 | 2011-01-31 | |
| US61/437,870 | 2011-01-31 | ||
| PCT/US2012/022847 WO2012106188A1 (en) | 2011-01-31 | 2012-01-27 | C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507422A JP2014507422A (ja) | 2014-03-27 |
| JP2014507422A5 true JP2014507422A5 (enExample) | 2015-02-26 |
| JP6000283B2 JP6000283B2 (ja) | 2016-09-28 |
Family
ID=45567146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551360A Expired - Fee Related JP6000283B2 (ja) | 2011-01-31 | 2012-01-27 | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8748415B2 (enExample) |
| EP (1) | EP2670764B1 (enExample) |
| JP (1) | JP6000283B2 (enExample) |
| CN (1) | CN103339141B (enExample) |
| BR (1) | BR112014010105A2 (enExample) |
| CA (1) | CA2826257A1 (enExample) |
| CY (1) | CY1116989T1 (enExample) |
| DK (1) | DK2670764T3 (enExample) |
| EA (1) | EA023578B1 (enExample) |
| ES (1) | ES2552512T3 (enExample) |
| HR (1) | HRP20151212T1 (enExample) |
| HU (1) | HUE026371T2 (enExample) |
| MX (1) | MX2013008359A (enExample) |
| PL (1) | PL2670764T3 (enExample) |
| PT (1) | PT2670764E (enExample) |
| RS (1) | RS54352B1 (enExample) |
| SI (1) | SI2670764T1 (enExample) |
| SM (1) | SMT201500303B (enExample) |
| WO (1) | WO2012106188A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014002936A (es) | 2011-09-21 | 2014-04-25 | Bristol Myers Squibb Co | Nuevos derivados de acido betulinico con actividad antiviral. |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| RU2516952C1 (ru) * | 2012-11-09 | 2014-05-20 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные |
| RU2519133C1 (ru) * | 2012-11-09 | 2014-06-10 | Леонид Леонидович Клопотенко | Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные |
| CN103214543B (zh) * | 2012-12-25 | 2015-09-02 | 中国人民解放军海军医学研究所 | 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用 |
| US20140221361A1 (en) * | 2013-02-06 | 2014-08-07 | Bristol-Myers Squibb Company | C-19 modified triterpenoids with hiv maturation inhibitory activity |
| CN105102468A (zh) * | 2013-02-25 | 2015-11-25 | 百时美施贵宝公司 | 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物 |
| PL3129392T3 (pl) | 2014-04-11 | 2021-04-06 | VIIV Healthcare UK(No.4) Limited | Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy |
| WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
| BR112017009850A2 (pt) * | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto |
| BR112017009853A2 (pt) * | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, uso de uma quantidade melhoradora de hiv de um composto |
| KR20170092581A (ko) | 2014-11-14 | 2017-08-11 | 비브 헬스케어 유케이 (넘버5) 리미티드 | Ｃ１７-아릴 치환된 베툴린산 유사체 |
| WO2016168447A1 (en) * | 2015-04-14 | 2016-10-20 | VIIV HEALTHCARE (No.4) LIMITED | Methods of producing an hiv maturation inhibitor |
| KR20180028535A (ko) * | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| EP3328876A1 (en) | 2015-07-28 | 2018-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Betuin derivatives for preventing or treating hiv infections |
| AU2016327169A1 (en) | 2015-09-24 | 2018-04-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds with hiv maturation inhibitory activity |
| JP2019502728A (ja) | 2016-01-20 | 2019-01-31 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ成熟阻害活性を有するルパンのアミン誘導体 |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| US20190135857A1 (en) * | 2016-06-30 | 2019-05-09 | Viiv Healthcare Uk (No. 5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| WO2019055119A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION |
| WO2019055280A1 (en) | 2017-09-13 | 2019-03-21 | Emmyon, Inc. | DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN |
| MX2020002884A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. |
| EP3784349B1 (en) | 2018-04-24 | 2023-12-27 | VIIV Healthcare UK (No.5) Limited | Compounds with hiv maturation inhibitory activity |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| US10343997B1 (en) | 2018-12-04 | 2019-07-09 | King Saud University | Ursolic acid derivatives |
| RU2020130238A (ru) | 2020-03-31 | 2022-03-14 | Феникс Байотекнолоджи, Инк. | Способ и композиции для лечения коронавирусной инфекции |
| EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| AU2005224260A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| CN101142227A (zh) * | 2004-11-12 | 2008-03-12 | 帕纳克斯医药公司 | 新颖的桦木醇衍生物、其制备和其用途 |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| ES2548905T3 (es) * | 2010-06-04 | 2015-10-21 | Bristol-Myers Squibb Company | Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH |
| EP2576585B8 (en) * | 2010-06-04 | 2016-12-21 | VIIV Healthcare UK (No.5) Limited | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| CA2826113C (en) * | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
-
2012
- 2012-01-27 SI SI201230354T patent/SI2670764T1/sl unknown
- 2012-01-27 EA EA201391098A patent/EA023578B1/ru not_active IP Right Cessation
- 2012-01-27 HU HUE12702946A patent/HUE026371T2/en unknown
- 2012-01-27 CN CN201280007020.0A patent/CN103339141B/zh not_active Expired - Fee Related
- 2012-01-27 WO PCT/US2012/022847 patent/WO2012106188A1/en not_active Ceased
- 2012-01-27 CA CA2826257A patent/CA2826257A1/en not_active Abandoned
- 2012-01-27 DK DK12702946.0T patent/DK2670764T3/en active
- 2012-01-27 MX MX2013008359A patent/MX2013008359A/es active IP Right Grant
- 2012-01-27 EP EP12702946.0A patent/EP2670764B1/en active Active
- 2012-01-27 RS RS20150740A patent/RS54352B1/sr unknown
- 2012-01-27 PL PL12702946T patent/PL2670764T3/pl unknown
- 2012-01-27 US US13/359,680 patent/US8748415B2/en not_active Expired - Fee Related
- 2012-01-27 JP JP2013551360A patent/JP6000283B2/ja not_active Expired - Fee Related
- 2012-01-27 BR BR112014010105A patent/BR112014010105A2/pt unknown
- 2012-01-27 PT PT127029460T patent/PT2670764E/pt unknown
- 2012-01-27 HR HRP20151212TT patent/HRP20151212T1/hr unknown
- 2012-01-27 ES ES12702946.0T patent/ES2552512T3/es active Active
-
2015
- 2015-12-01 SM SM201500303T patent/SMT201500303B/it unknown
- 2015-12-01 CY CY20151101099T patent/CY1116989T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507422A5 (enExample) | ||
| JP2014503595A5 (enExample) | ||
| JP2015510515A5 (enExample) | ||
| JP2013527243A5 (enExample) | ||
| JP2013527242A5 (enExample) | ||
| JP2016509062A5 (enExample) | ||
| ES2552512T3 (es) | Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana | |
| JP2016507558A5 (enExample) | ||
| JP2014526554A5 (enExample) | ||
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| JP2013507425A5 (enExample) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| JP2017505314A5 (enExample) | ||
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| RU2013116801A (ru) | Ингибиторы notum пектинацетилэстеразы и способы их применения | |
| CY1119727T1 (el) | Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων | |
| JP2018513150A5 (enExample) | ||
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| CA2864098A1 (en) | Spiro[2.4]heptanes for treatment of flaviviridae infections | |
| JP2011526924A5 (enExample) | ||
| EA201291301A1 (ru) | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич | |
| JP2009544708A5 (enExample) | ||
| JP2013522229A5 (enExample) |